Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
Номер патента: MY189028A
Опубликовано: 20-01-2022
Автор(ы): Andreas Loew, David Glass, David L Porter, Jennifer BROGDON, Jiquan Zhang, Joan Mannick, Leon Murphy, Marco RUELLA, Michael MILONE, Qilong WU, Saad KENDERIAN, Saar GILL, Yongqiang Wang
Принадлежит: NOVARTIS AG, Univ Pennsylvania
Опубликовано: 20-01-2022
Автор(ы): Andreas Loew, David Glass, David L Porter, Jennifer BROGDON, Jiquan Zhang, Joan Mannick, Leon Murphy, Marco RUELLA, Michael MILONE, Qilong WU, Saad KENDERIAN, Saar GILL, Yongqiang Wang
Принадлежит: NOVARTIS AG, Univ Pennsylvania
Реферат: The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.
Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment.
Номер патента: MX2017002205A. Автор: Wang Yongqiang,Glass David,Loew Andreas,Murphy Leon,GILL Saar,BROGDON Jennifer,Mannick Joan,Ruella Marco,Wu Qilong,Milone Michael,Kenderian Saad,Zhang Jiquan,L Porter David. Владелец: NOVARTIS AG. Дата публикации: 2017-08-21.